Admedus : appoints Genpharm as CardioCel distributor in MENA

ASX RELEASE

 Genpharm to sell CardioCel® in the Middle East and North Africa (MENA)

 Agreement strengthens Admedus' global launch strategy for CardioCel®

Brisbane, Australia, 22nd April 2015

Admedus Limited (ASX: AHZ) today announced that it has appointed Genpharm (Dubai, UAE), a specialty marketing and sales healthcare company as its exclusive partner for CardioCel® in the Middle East and North Africa region.
"Admedus is highly strategic in the selection and appointment of specialist distributors in regions where we do not have a direct sales force. This forms an important part of our global launch strategy for CardioCel" said Admedus CEO Mr. Lee Rodne. "Genpharm has a strong reputation and presence in the region and we look forward to broadening CardioCel®'s availability globally."
Genpharm is a specialty healthcare company focusing on market access in the
Middle East and North Africa, one of the fastest growing healthcare regions globally.
Admedus and Genpharm will be able to leverage Admedus' existing regulatory approvals from outside the region. MENA is a fast-growing region and its eight largest countries have a combined population of over 120 million people. The agreement significantly strengthens CardioCel®'s opportunity in the region.
"We feel excited to partner with Admedus in bringing CardioCel to the MENA region for the repair of heart defects in both children and adult patients. We are both committed to improving the quality of life for these patients," said Mr Karim Smaira, Genpharm managing partner.
The expansion of CardioCel into the MENA region expands the growing number of centres using CardioCel globally, to treat and repair heart defects. There are currently 31 centres in Europe and 31 centres in the USA, and recent approvals for use in Canada and Hong Kong.
Follow us:
Twitter: @Admedus
Facebook: www.facebook.com/pages/Admedus

Dr Julian Chick | Chief Operating Officer | Admedus Limited
Tel: +61 3 9620 5454

+61 (0) 423 139 163
hprice@admedus.com

Consilium Strategic Communications
Jessica Hodgson / Ivar Milligan
+44 (0)20 3709 5700 admedus@consilium-comms.com

Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.
Further information on the company can be found on www.admedus.com

CardioCel® is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects.
It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair heart valves. CardioCel® has
been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting
that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.
CardioCel® is the Admedus Group's lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group's proprietary ADAPT® tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation.

Genpharm is a specialty pharmaceutical marketing company. It provides fast- track market access to innovative and specialty pharmaceutical companies looking to expand into the Middle East and North Africa (MENA) region. Genpharm focuses on areas of unmet medical need, particularly in rare and genetic diseases with niche and orphan drugs. Genpharm operates exclusively
through evidence-based medicine and high ethical standards. With an experienced management and a team of dedicated MSLs Genpharm has

operations extending across the Middle East and North Africa region. Genpharm's current partners include GSK, Genzyme, Aegerion, Stallergenes, Tigenix, Lifecodexx and Sintetica. Genpharm is based in the Dubai Biotechnology and Research Park (DuBiotech), U.A.E.
For more information please call +971 4 4227010 or visit us at www.genpharmservices.com

distributed by